201 related articles for article (PubMed ID: 8674173)
1. Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease.
Böcker D; Haverkamp W; Block M; Borggrefe M; Hammel D; Breithardt G
Circulation; 1996 Jul; 94(2):151-7. PubMed ID: 8674173
[TBL] [Abstract][Full Text] [Related]
2. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
Kühlkamp V; Mewis C; Mermi J; Bosch RF; Seipel L
J Am Coll Cardiol; 1999 Jan; 33(1):46-52. PubMed ID: 9935007
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest.
Haverkamp W; Martinez-Rubio A; Hief C; Lammers A; Mühlenkamp S; Wichter T; Breithardt G; Borggrefe M
J Am Coll Cardiol; 1997 Aug; 30(2):487-95. PubMed ID: 9247523
[TBL] [Abstract][Full Text] [Related]
4. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
[TBL] [Abstract][Full Text] [Related]
5. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
[TBL] [Abstract][Full Text] [Related]
6. Prospective clinical evaluation and follow-up of a cohort of consecutive VT/VF patients, using a staged-care protocol, including coronary arteriography, programmed electrical stimulation and cardiac surgery.
Naccarella F; Rolli A; Carboni A; Finardi A; Aurier E; Favaro L; Contini S; Gherli T; Caponi D; Maranga SS; Lepera G; Bartoletti A
G Ital Cardiol; 1999 Oct; 29(10):1142-56. PubMed ID: 10546124
[TBL] [Abstract][Full Text] [Related]
7. The role of EP-guided therapy in ventricular arrhythmias: beta-blockers, sotalol, and ICD's.
Capucci A; Aschieri D; Villani GQ
J Interv Card Electrophysiol; 2000 Jan; 4 Suppl 1():57-63. PubMed ID: 10590490
[TBL] [Abstract][Full Text] [Related]
8. Gender differences in ventricular arrhythmia recurrence in patients with coronary artery disease and implantable cardioverter-defibrillators.
Lampert R; McPherson CA; Clancy JF; Caulin-Glaser TL; Rosenfeld LE; Batsford WP
J Am Coll Cardiol; 2004 Jun; 43(12):2293-9. PubMed ID: 15193696
[TBL] [Abstract][Full Text] [Related]
9. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator.
Seidl K; Hauer B; Schwick NG; Zahn R; Senges J
Am J Cardiol; 1998 Sep; 82(6):744-8. PubMed ID: 9761084
[TBL] [Abstract][Full Text] [Related]
10. Comparison of event rates and survival in patients with unexplained syncope without documented ventricular tachyarrhythmias versus patients with documented sustained ventricular tachyarrhythmias both treated with implantable cardioverter-defibrillators.
Pires LA; May LM; Ravi S; Parry JT; Lal VR; Nino CL
Am J Cardiol; 2000 Mar; 85(6):725-8. PubMed ID: 12000047
[TBL] [Abstract][Full Text] [Related]
11. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.
Kettering K; Mewis C; Dörnberger V; Vonthein R; Bosch RF; Kühlkamp V
Pacing Clin Electrophysiol; 2002 Nov; 25(11):1571-6. PubMed ID: 12494613
[TBL] [Abstract][Full Text] [Related]
13. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%.
Grimm W; Hoffmann J Jü; Müller HH; Maisch B
J Am Coll Cardiol; 2002 Mar; 39(5):780-7. PubMed ID: 11869841
[TBL] [Abstract][Full Text] [Related]
14. Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias.
Mewis C; Kühlkamp V; Mermi J; Bosch RF; Seipel L
J Am Coll Cardiol; 1999 Jun; 33(7):1989-95. PubMed ID: 10362204
[TBL] [Abstract][Full Text] [Related]
15. Ventricular tachycardia or ventricular fibrillation occurs less often in patients with left bundle branch block and combined resynchronization and defibrillators than in patients with narrow QRS and conventional defibrillators.
Blaschke F; Knaus T; Celebi O; Krebs A; Nitardy A; Habedank D; Dietz R; Stockburger M
Europace; 2012 Feb; 14(2):224-9. PubMed ID: 21946820
[TBL] [Abstract][Full Text] [Related]
16. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial.
Raitt MH; Connor WE; Morris C; Kron J; Halperin B; Chugh SS; McClelland J; Cook J; MacMurdy K; Swenson R; Connor SL; Gerhard G; Kraemer DF; Oseran D; Marchant C; Calhoun D; Shnider R; McAnulty J
JAMA; 2005 Jun; 293(23):2884-91. PubMed ID: 15956633
[TBL] [Abstract][Full Text] [Related]
17. Follow-up of patients with unexplained syncope and inducible ventricular tachyarrhythmias: analysis of the AVID registry and an AVID substudy. Antiarrhythmics Versus Implantable Defibrillators.
Steinberg JS; Beckman K; Greene HL; Marinchak R; Klein RC; Greer SG; Ehlert F; Foster P; Menchavez E; Raitt M; Wathen MS; Morris M; Hallstrom A
J Cardiovasc Electrophysiol; 2001 Sep; 12(9):996-1001. PubMed ID: 11573709
[TBL] [Abstract][Full Text] [Related]
18. The implantable cardioverter defibrillator and primary prevention of sudden death: the Multicenter Automatic Defibrillator Implantation Trial and the Coronary Artery Bypass Graft (CABG)-Patch Trial.
Block M; Breithardt G
Am J Cardiol; 1999 Mar; 83(5B):74D-78D. PubMed ID: 10089844
[TBL] [Abstract][Full Text] [Related]
19. Clinical and electrophysiologic predictors of ventricular tachyarrhythmia recurrence in patients with implantable cardioverter defibrillators.
Gillis AM; Sheldon RS; Wyse DG; Duff HJ; Cassidy MR; Mitchell LB
J Cardiovasc Electrophysiol; 2003 May; 14(5):492-8. PubMed ID: 12776866
[TBL] [Abstract][Full Text] [Related]
20. Ventricular fibrillation induced by low-energy shocks from programmable implantable cardioverter-defibrillators in patients with coronary artery disease.
Lauer MR; Young C; Liem LB; Ottoboni L; Peterson J; Goold P; Sung RJ
Am J Cardiol; 1994 Mar; 73(8):559-63. PubMed ID: 8147300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
